V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Ginkgo Bioworks Holdings Executive Compensation (FY25)

DNA · Executive and director compensation, fiscal 2023 to 2025
Chief executive, fiscal 2025
◇
Jason Kelly
Latest say-on-pay support
=
June 11, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in one industry, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Ginkgo Bioworks Holdings

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 13, 2026Latest filing (8-K): June 12, 2026
7 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Ginkgo Bioworks Holdings brief$1,500Get the executive brief
Velarion Member, one year
141 figures on this page: 137 cited to the filing that reported them, 4 calculated from figures it prints. See the citations

More on Ginkgo Bioworks Holdings

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Jason Kelly: $1,231,000 → $5,709,049
Say-on-pay support: 99.2% → 88.4% (10.8 points lower)
CEO pay ratio: 1.4:1 → 32:1

Frequently asked questions

Answers drawn from the data on this page.
Who is Ginkgo Bioworks Holdings' chief executive and what were they paid?
Jason Kelly, Chief Executive Officer, received $5,709,049 in total compensation for fiscal 2025. Compared with the $1,231,000 reported for fiscal 2024, Kelly's total was up.
What was Ginkgo Bioworks Holdings' say-on-pay result?
Shareholders supported the say-on-pay proposal with 88.4% of votes cast for or against in favor at the meeting held June 11, 2026 for fiscal 2025.
Which companies are in Ginkgo Bioworks Holdings' peer group?
The disclosed peer group includes AbCellera Biologics Inc., Akoya Biosciences, Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG and Flotek Industries, Inc., among others. The 2026 Peer Group includes Adaptive Biotechnologies Corporation, Certara, Inc., Codexis, Inc., Cytek Biosciences, Inc. and Fulgent Genetics, Inc., among others. The additional disclosed peer group names Maravai LifeSciences Holdings Inc. and Standard BioTools, Inc.
What is Ginkgo Bioworks Holdings' chief executive pay ratio?
The company reported a chief executive pay ratio of 32:1 for fiscal 2025, against median employee compensation of $176,436.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mark Dmytruk
Chief Financial Officer
◇—◇———◇◇
Reshma Shetty
President
◇—————◇◇
Jason Kelly
Chief Executive Officer
◇—————◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mark Dmytruk
Former Chief Financial Officer
◇—◇————◇
Jason Kelly
Chief Executive Officer
◇——◇———◇
Reshma Shetty
President and Former Chief Operating Officer
◇——◇———◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jason Kelly
Chief Executive Officer
◇—◇———◇◇
Reshma Shetty
President and Former Chief Operating Officer
◇—◇———◇◇
Steven Coen
Chief Financial Officer
◇—◇———◇◇
Mark Dmytruk
Former Chief Financial Officer
Departed during or after this year
◇—◇———◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Jason KellyPSU◇◇◇———◇
Mark DmytrukRSU◇——◇——◇
Mark DmytrukPSU◇◇◇———◇
Reshma ShettyPSU◇◇◇———◇
Steven CoenPSU◇◇◇———◇
Steven CoenPSU◇◇◇———◇
Steven CoenRSU◇——◇——◇
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Jason KellyRSU◇◇——
RSU◇◇——
RSU◇◇——
Steven CoenRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Reshma ShettyRSU◇◇——
RSU◇◇——
RSU◇◇——
Mark DmytrukRSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Reshma Shetty
President and Former Chief Operating Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Change-in-control trigger◇
Excise tax treatment◇
Steven Coen
Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Change-in-control trigger◇
Excise tax treatment◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Shyam Sankar
Board chair
◇—◇———◇
Christian Henry
◇—◇———◇
Ross Fubini
◇—◇———◇
Harry E. Sloan
◇—◇———◇
Sri Kosuri
◇—◇———◇
Kathy Hopinkah Hannan
◇—————◇
Myrtle Potter
◇—————◇
Reshma Shetty and Jason Kelly served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • AbCellera Biologics Inc. ABCL
  • Akoya Biosciences, Inc. AKYA
  • Beam Therapeutics Inc. BEAM
  • CRISPR Therapeutics AG CRSP
  • Flotek Industries, Inc. FTK
  • Harvard Bioscience, Inc. HBIO
  • Pacific Biosciences of California, Inc. PACB
  • Perimeter Solutions, Inc. PRM
  • Quanterix Corporation QTRX
  • Sangamo Therapeutics, Inc. SGMO
  • Schrodinger, Inc. SDGR
  • Seres Therapeutics, Inc. MCRB
  • Travere Therapeutics, Inc. TVTX
  • Twist Bioscience Corporation TWST
  • Ultragenyx Pharmaceutical Inc. RARE
  • Vir Biotechnology, Inc. VIR
2026 Peer Group
  • Adaptive Biotechnologies Corporation ADPT
  • Certara, Inc. CERT
  • Codexis, Inc. CDXS
  • Cytek Biosciences, Inc. CTKB
  • Fulgent Genetics, Inc. FLGT
  • Lifecore Biomedical, Inc. LFCR
  • Mesa Laboratories, Inc. MLAB
  • Personalis, Inc. PSNL
  • PROCEPT BioRobotics Corporation PRCT
  • Recursion Pharmaceuticals, Inc. RXRX
Additional disclosed peer group
  • Maravai LifeSciences Holdings Inc. MRVI
  • Standard BioTools, Inc. LAB

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 11, 2026=◇◇◇
2024June 12, 2025=◇◇◇
2023June 13, 2024=◇◇◇
2022June 16, 2023=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Jason Kelly (Chief Executive Officer), FY2025 total compensation $5,709,049 (base salary $250,000) [exec_comp, SEC accession 0001628280-26-028377, filed 2026-04-29]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Ginkgo Bioworks Holdings files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Ginkgo Bioworks Holdings disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Ginkgo Bioworks Holdings sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Ginkgo Bioworks Holdings' disclosed peer group is defensible, who names Ginkgo Bioworks Holdings back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
141 figures on this page: 137 cited to the filing that reported them, 4 calculated from figures it prints.
137 cited to the filing
4 calculated from the filing

Documents cited

  1. 0001628280-26-042932
  2. 0001628280-26-028377
    ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION · CEO Pay Ratio · Compensation Discussion and Analysis · Compensation of Directors · and 3 more sections
  3. 0001628280-25-031304
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001628280-25-020648
    Summary Compensation Table
  5. 0001628280-24-028287
  6. 0001628280-24-018970
    Summary Compensation Table
  7. 0000950170-23-028975
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Ginkgo Bioworks Holdings executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/DNA (accessed 2026).
Short form: data: Velarion

The paid brief for Ginkgo Bioworks Holdings

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Ginkgo Bioworks Holdings and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Ginkgo Bioworks Holdings discloses

The companies named in DNA's own disclosed peer group.

AbCellera Biologics Inc.Beam Therapeutics Inc.CRISPR Therapeutics AGFlotek Industries, Inc.Harvard Bioscience, Inc.Pacific Biosciences of California, Inc.Perimeter Solutions, Inc.Quanterix CorporationSchrodinger, Inc.Seres Therapeutics, Inc.Travere Therapeutics, Inc.Twist Bioscience CorporationUltragenyx Pharmaceutical Inc.Vir Biotechnology, Inc.Adaptive Biotechnologies CorporationCertara, Inc.Codexis, Inc.Cytek Biosciences, Inc.Fulgent Genetics, Inc.Lifecore Biomedical, Inc.Mesa Laboratories, Inc.Personalis, Inc.PROCEPT BioRobotics CorporationRecursion Pharmaceuticals, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy